Some mTOR inhibitors have been tested for treatment of HCC but have failed in clinical trials, and several new inhibitors on the PI3K/AKT/mTOR pathway are now in clinical trials for HCC patients [13]. This evidence concerns the gene PIK3CB and hepatocellular carcinoma.